Skip to main content

Table 3 Outcomes across the duration of the study

From: Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes

Month

Pre-treatment

Baseline

Post- treatment

ANOVA

0

1

2

3

4

5

6

7

8

9

10

11

Corr.

Uncorr.

Red days

15.2 (0.9, 7.7)

15.4 (0.8, 7.7)

15.7 (0.9, 8.2)

12.3 (0.9, 8.6)

10.6 (0.9, 8.4)

8.6 (0.73, 6.8)

8.6 (0.9,7.9)

7.8 (0.9,7.6)

6.7 (0.84,5.9)

5.7 (0.8,5.3)

5.0 (0.7,4.0)

4.9 (0.8,4.3)

p=0.001

p< 0.001

Amber days

10.9 (0.9, 7.9)

11.2 (0.8, 7.6)

11.0 (0.8, 7.6)

11.3 (0.9, 8.2)

11.1 (0.9, 7.9)

11.9 (0.7, 8.1)

11.3 (0.9, 8.5)

12.3 (1.0, 8.9)

11.6 (1.2, 8.7)

11.9 (0.7, 8.7)

11.7 (0.7, 8.9)

12.3 (1.8, 9.2)

p=1.000

p=0.985

Green days

3.3 (0.6, 4.7)

3.2 (0.5, 4.9)

3.6 (0.5, 5.4)

6.7 (0.8, 8.2)

8.4 (1.0, 9.2)

9.6 (1.0, 9.2)

10.4 (1.1, 9.6)

10.2 (1.1, 9.7)

11.6 (1.3, 9.0)

12.4 (1.4, 9.1)

13.4 (1.7, 9.7)

12.4 (1.9, 10.0)

p=0.001

p< 0.001

Triptan days

7.2 (0.9, 7.9)

7.7 (0.8, 8.0)

8.1 (0.9, 8.8)

5.7 (0.7, 7.2)

5.0 (0.7, 6.9)

4.6 (0.7, 6.0)

5.0 (0.8, 7.0)

4.5 (0.8, 6.4)

4.1 (0.7, 5.1)

4.1 (0.7, 4.8)

4.2 (0.8, 4.4)

4.2 (0.9, 4.9)

p=0.001

p< 0.001

Painkiller days

18.7 (1.2, 11.6)

14.7 (1.2, 11.4)

13.9 (1.2, 11.5)

13.0 (1.2, 11.0)

11.6 (1.1, 10.8)

11.3 (1.1, 10.2)

10.8 (1.1, 10.2)

10.2 (1.1, 10.1)

9.4 (1.4, 10.0)

8.5 (1.5, 10.0)

8.6 (1.8, 9.8)

9.1 (1.9, 9.8)

p=0.001

p< 0.001

HIT6 score

67.5 (0.7, 5.4)

66.6 (0.8, 8.0)

66.9 (1.0, 9.4)

62.4 (1.0, 10.4)

60.3 (1.2, 11.2)

59.1 (1.3, 11.7)

58.8 (1.2, 11.3)

60.0 (1.0, 8.5)

59.0 (1.1, 7.9)

58.6 (1.4, 9.2)

58.1 (1.9, 10.5)

57.5 (1.9, 9.7)

p=0.001

p< 0.001

PHQ9 score

16.7 (1.0, 7.8)

16.1 (0.7, 6.5)

16.5 (0.7, 6.4)

13.4 (0.7, 6.7)

12.1 (0.7, 6.7)

11.0 (0.7, 6.0)

10.5 (0.6, 5.8)

10.0 (0.7, 6.2)

9.6 (0.9, 6.1)

9.3 (0.9, 6.4)

9.2 (1.3, 7.0)

8.5 (1.2, 6.1)

p=0.001

p< 0.001

PDI score

44.1 (2.0, 16.6)

44.8 (1.7, 16.6)

45.8 (1.7, 16.8)

38.7 (2.0, 20.0)

35.1 (2.0, 19.1)

32.6 (2.3, 20.7)

33.3 (2.3, 20.7)

31.4 (2.4, 20.4)

29.4 (2.6, 18.3)

29.4 (3.2, 21.7)

28.0 (3.8, 20.8)

28.0 (4.3, 22.0)

p=0.001

p< 0.001

t- test

(Red days)

t value

   

9.6

  

7.0

  

7.6

  

Corrected

   

p=0.001

  

p=0.001

  

p=0.001

  
 

Uncorrected

   

p< 0.001

  

p< 0.001

  

p< 0.001

  
  1. Values are mean (SE, SD)
  2. Raw data for all outcomes. 98 patients received at least one dose of erenumab and were analysed. Three months of pre-treatment data were collected, with month 2 used as baseline. Outcomes are recorded up to nine months of treatment (month 11), and relate to the mean number of red days (headache limiting activities of daily living), amber days (headache but no limitation to activities of daily living), green days (headache-free), triptan days (requiring use of one or more triptans), painkiller days (requiring use of simple and/or opiate analgesics), HIT-6 (headache impact test-6) score, PHQ-9 (patient health questionnaire-9) score, and PDI (pain disability index) score. Analysis of variance p values are shown for each outcome, both corrected following Bonferroni calculation for multiple comparisons, and uncorrected. Below, t tests comparing mean scores relating to the change in number of red days per patient at month 5, 8 and 11 (three, six and nine months post-treatment, respectively) compared with baseline (month 2) are shown
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us